NEURONETICS INC (STIM)
US64131A1051 - Common Stock
We assign a fundamental rating of 2 out of 10 to STIM. STIM was compared to 188 industry peers in the Health Care Equipment & Supplies industry. Both the profitability and financial health of STIM have multiple concerns. STIM is valied quite expensively at the moment, while it does show a decent growth rate.
1. Profitability
1.1 Basic Checks
STIM had negative earnings in the past year.
STIM had a negative operating cash flow in the past year.
In the past 5 years STIM always reported negative net income.
In the past 5 years STIM always reported negative operating cash flow.
1.2 Ratios
STIM has a Return On Assets (-33.54%) which is comparable to the rest of the industry.
Looking at the Return On Equity, with a value of -167.50%, STIM is doing worse than 77.54% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -33.54% | ||
| ROE | -167.5% | ||
| ROIC | N/A |
ROA(3y)-26.65%
ROA(5y)-28.76%
ROE(3y)-63.33%
ROE(5y)-71.65%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
Looking at the Gross Margin, with a value of 75.91%, STIM belongs to the top of the industry, outperforming 86.63% of the companies in the same industry.
STIM's Gross Margin has been stable in the last couple of years.
STIM does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 75.91% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.81%
GM growth 5Y-1.05%
2. Health
2.1 Basic Checks
STIM does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for STIM has been increased compared to 1 year ago.
The number of shares outstanding for STIM has been increased compared to 5 years ago.
Compared to 1 year ago, STIM has a worse debt to assets ratio.
2.2 Solvency
Based on the Altman-Z score of -5.13, we must say that STIM is in the distress zone and has some risk of bankruptcy.
STIM has a Altman-Z score of -5.13. This is in the lower half of the industry: STIM underperforms 68.98% of its industry peers.
STIM has a Debt/Equity ratio of 2.38. This is a high value indicating a heavy dependency on external financing.
STIM's Debt to Equity ratio of 2.38 is on the low side compared to the rest of the industry. STIM is outperformed by 86.10% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 2.38 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -5.13 |
ROIC/WACCN/A
WACC10.2%
2.3 Liquidity
A Current Ratio of 2.58 indicates that STIM has no problem at all paying its short term obligations.
With a Current ratio value of 2.58, STIM perfoms like the industry average, outperforming 47.06% of the companies in the same industry.
A Quick Ratio of 2.37 indicates that STIM has no problem at all paying its short term obligations.
STIM's Quick ratio of 2.37 is in line compared to the rest of the industry. STIM outperforms 57.22% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.58 | ||
| Quick Ratio | 2.37 |
3. Growth
3.1 Past
STIM shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 8.47%, which is quite good.
STIM shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 9.41%.
Measured over the past years, STIM shows a small growth in Revenue. The Revenue has been growing by 6.21% on average per year.
EPS 1Y (TTM)8.47%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%12.12%
Revenue 1Y (TTM)9.41%
Revenue growth 3Y13.16%
Revenue growth 5Y6.21%
Sales Q2Q%3.61%
3.2 Future
STIM is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 17.41% yearly.
The Revenue is expected to grow by 16.19% on average over the next years. This is quite good.
EPS Next Y16.35%
EPS Next 2Y18.5%
EPS Next 3Y17.41%
EPS Next 5YN/A
Revenue Next Year9.92%
Revenue Next 2Y11%
Revenue Next 3Y12.12%
Revenue Next 5Y16.19%
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for STIM. In the last year negative earnings were reported.
Also next year STIM is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A more expensive valuation may be justified as STIM's earnings are expected to grow with 17.41% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y18.5%
EPS Next 3Y17.41%
5. Dividend
5.1 Amount
No dividends for STIM!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
NEURONETICS INC
NASDAQ:STIM (11/13/2024, 5:27:12 PM)
After market: 0.6222 +0.01 (+2.07%)0.6096
-0.08 (-11.65%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap18.48M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -33.54% | ||
| ROE | -167.5% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 75.91% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.74
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 2.38 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 2.58 | ||
| Quick Ratio | 2.37 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
High Growth Momentum
Growth
EPS 1Y (TTM)8.47%
EPS 3YN/A
EPS 5Y
EPS Q2Q%
EPS Next Y16.35%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)9.41%
Revenue growth 3Y13.16%
Revenue growth 5Y
Sales Q2Q%
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y